Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers: anaplastic thyroid...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Gazzah, Anas, Lassen, Ulrik, Stein, Alexander, Wen, Patrick Y., Dietrich, Sascha, de Jonge, Maja J. A., Blay, Jean-Yves, Italiano, Antoine, Yonemori, Kan, Cho, Daniel C., de Vos, Filip Y. F. L., Moreau, Philippe, Fernandez, Elena Elez, Schellens, Jan H. M., Zielinski, Christoph C., Redhu, Suman, Boran, Aislyn, Passos, Vanessa Q., Ilankumaran, Palanichamy, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202803/
https://www.ncbi.nlm.nih.gov/pubmed/37059834
http://dx.doi.org/10.1038/s41591-023-02321-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202803/
https://www.ncbi.nlm.nih.gov/pubmed/37059834
http://dx.doi.org/10.1038/s41591-023-02321-8

Ejemplares similares